Telomir Pharmaceuticals, Inc. Common StockTELONASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
1672.98%
↑ 1065% above average
Average (14q)
143.58%
Historical baseline
Range
High:1672.98%
Low:-87.29%
Volatility
1226.0%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 1672.98% |
| Q2 2025 | -87.29% |
| Q1 2025 | 25.24% |
| Q4 2024 | -57.11% |
| Q3 2024 | 5.49% |
| Q2 2024 | -26.02% |
| Q1 2024 | 294.55% |
| Q4 2023 | -22.39% |
| Q3 2023 | -60.67% |
| Q2 2023 | 51.62% |
| Q1 2023 | -7.75% |
| Q4 2022 | 107.75% |
| Q3 2022 | 246.45% |
| Q2 2022 | 10.82% |
| Q1 2022 | 0.00% |